{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:54:24Z","timestamp":1791262464583,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110445","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:35:21Z","timestamp":1788478521000},"page":"110445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Atom-based 3D-QSAR, pharmacophore modelling and molecular dynamics guided identification of thienopyrimidinone derivatives targeting EGFR in breast cancer"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9661-9921","authenticated-orcid":false,"given":"Shashikant V.","family":"Bhandari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutuja R.","family":"Napte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital M.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal D.","family":"Sadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul B.","family":"Shirsath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddesh S.","family":"Wagdarikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani R.","family":"Atkare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somdatta Y.","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.110445_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110445_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"6797","key":"10.1016\/j.bioorg.2026.110445_bb0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110445_bb0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2164-7-96","article-title":"The molecular portraits of breast tumors are conserved across microarray platforms","volume":"7","author":"Hu","year":"2006","journal-title":"BMC Genomics"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110445_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","article-title":"Deconstructing the molecular portraits of breast cancer","volume":"5","author":"Prat","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110445_bb0030","doi-asserted-by":"crossref","unstructured":"Brigham & Women's Hospital & Harvard Medical School Chin Lynda 9 11 Park Peter J. 12 Kucherlapati Raju 13, Genome data analysis: Baylor College of Medicine Creighton Chad J. 22 23 Donehower Lawrence A. 22 23 24 25, Institute for Systems Biology Reynolds Sheila 31 Kreisberg Richard B. 31 Bernard Brady 31 Bressler Ryan 31 Erkkila Timo 32 Lin Jake 31 Thorsson Vesteinn 31 Zhang Wei 33 Shmulevich Ilya 31, Oregon Health & Science University Anur Pavana 37 Spellman Paul T. 37. Comprehensive molecular portraits of human breast tumours, Nature 490(7418) (2012) 61\u201370, doi: https:\/\/doi.org\/10.1038\/nature11412.","DOI":"10.1038\/nature11412"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110445_bb0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110445_bb0040","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110445_bb0045","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110445_bb0050","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrclinonc.2009.166","article-title":"Histological and molecular types of breast cancer: is there a unifying taxonomy?","volume":"6","author":"Weigelt","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110445_bb0055","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","article-title":"Basal-like breast cancer: a critical review","volume":"26","author":"Rakha","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110445_bb0060","first-page":"1393","volume":"28","author":"Costa","year":"2013","journal-title":"Histol. Histopathol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110445_bb0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000516114","article-title":"Gallen\/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer","volume":"16","author":"Thomssen","year":"2021","journal-title":"Breast Care"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110445_bb0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","article-title":"Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry","volume":"139","author":"Inwald","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110445_bb0075","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel\u2013treated advanced triple-negative breast cancer","volume":"113","author":"Rugo","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110445_bb0080","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110445_bb0085","first-page":"514","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New England","volume":"382","author":"Slamon","year":"2020","journal-title":"J. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110445_bb0090","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110445_bb0095","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1470-2045(11)70335-7","article-title":"Genetic heterogeneity and cancer drug resistance","volume":"13","author":"Turner","year":"2012","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110445_bb0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110445_bb0105","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110445_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70061","article-title":"Design, synthesis and molecular docking of new thieno[2,3-d]pyrimidin-4-one derivatives as dual EGFR and FGFR inhibitors","volume":"86","author":"Sultan","year":"2025","journal-title":"Drug Dev. Res."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110445_bb0115","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1055\/a-2641-3646","article-title":"Design and synthesis of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-sulfonamide derivatives using p-phenylenediamine as a linker","volume":"57","author":"Akhtar","year":"2025","journal-title":"Synthesis"},{"key":"10.1016\/j.bioorg.2026.110445_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118435","article-title":"Fused thiophene-benzimidazole conjugates targeting EGFR: design, synthesis, anticancer evaluation and their mechanistic insights","volume":"303","author":"Chandrakanth","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0125","article-title":"Investigation of the anticancer, antimigration and antiangiogenesis effects of an oxadiazole derivative in two- and three-dimensional cultured Ishikawa and HUVEC cells: in vitro and in silico studies","volume":"55","author":"B\u00fclb\u00fcl","year":"2024","journal-title":"Acta Med. Cordoba"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110445_bb0130","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1039\/D5MD00454C","article-title":"Design, synthesis, and apoptotic antiproliferative efficacy of new quinazoline\/1,3,4-oxadiazole-2-thione derived EGFR\/HER-2 dual inhibitors with anti-breast cancer activity","volume":"16","author":"Gomaa","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110445_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.69857\/joapr.v13i2.1008","article-title":"Exploring 1,3,4-oxadiazole derivatives for hepatocellular carcinoma: synthesis, and bioactivity evaluation","volume":"13","author":"Patidar","year":"2025","journal-title":"J. Appl. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.110445_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2025.102217","article-title":"Rational design, and synthesis of imidazole ring incorporated pyridine-1,2,4-oxadiazole derivatives: in-vitro anticancer evaluation and in-silico molecular docking simulations","volume":"15","author":"Vasamsetti","year":"2025","journal-title":"Results Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110445_bb0145","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2174\/1570180820666230410083544","article-title":"Molecular modeling of some 1,3,4-oxadiazole derivatives as EGFR inhibitors for the treatment of cancer","volume":"21","author":"Patil","year":"2024","journal-title":"Lett Drug Des Discov."},{"key":"10.1016\/j.bioorg.2026.110445_bb0150","doi-asserted-by":"crossref","first-page":"11870","DOI":"10.1039\/D5NJ01451D","article-title":"Synthesis and evaluation of edaravone-1,3,4-oxadiazole derivatives as potential anti-cancer inhibitors","volume":"49","author":"Reddy","year":"2025","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2025.134709","article-title":"Design, synthesis, in silico ADME, toxicity prediction, molecular docking studies of 1,2,4-oxadiazole incorporated indolizine-thiadiazole derivatives and their biological evaluation as anticancer agents","volume":"183","author":"Ketha","year":"2025","journal-title":"Tetrahedron"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110445_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03331024231219475","article-title":"The shortcoming of using glibenclamide in exploratory clinical headache provocation studies","volume":"43","author":"Christophersen","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.bioorg.2026.110445_bb0165","article-title":"Design, synthesis, characterization, in vitro anticancer evaluation, computational studies, and in silico ADME assessment of new N-(5-o-tolyl-1,3,4-oxadiazol-2-yl) alkanamides","volume":"54","author":"Kadeer","year":"2024","journal-title":"Chem. Data Collect."},{"key":"10.1016\/j.bioorg.2026.110445_bb0170","article-title":"Design, synthesis, antiproliferative assessments, and computational studies of new quinolin-2(1H)-ones as dual EGFR\/HER-2 inhibitors","volume":"13","author":"Al-Wahaibi","year":"2025","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0175","first-page":"51","article-title":"New oxadiazole and pyrazoline derivatives as anti-proliferative agents targeting EGFR-TK: design, synthesis, biological evaluation and molecular docking study","volume":"33","author":"Serag","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110445_bb0180","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00044-024-03325-w","article-title":"Design, synthesis, molecular docking, and antibacterial activity of novel amide-linked tetrahydrobenzothienopyrimidinone derivatives as potential DNA gyrase and topoisomerase IV inhibitors","volume":"34","author":"Mohamed","year":"2025","journal-title":"Med. Chem. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110445_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19095298","article-title":"Expression of VEGF, EGF, and their receptors in squamous esophageal mucosa, with correlations to histological findings and endoscopic minimal changes, in patients with different GERD phenotypes","volume":"19","author":"Wasielica-Berger","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110445_bb0190","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1039\/D5RA07556D","article-title":"Design, synthesis, in silico studies, and antiproliferative activity of a novel series of thiazole\/1,2,3-triazole hybrids as apoptosis inducers and multi-kinase inhibitors endowed with anti-breast cancer activity","volume":"16","author":"Mohamed","year":"2026","journal-title":"RSC Adv."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110445_bb0195","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1039\/D4MD00055B","article-title":"Computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy","volume":"15","author":"Khedkar","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110445_bb0200","article-title":"Synthesis, cytotoxic effect assessment and molecular docking studies of disubstituted thiadiazole including oxadiazole as hybrid component","volume":"42","author":"Hassanzadeh","year":"2022","journal-title":"J. Rep. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110445_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117729","article-title":"First-in-class dual inhibitors of MASTL and Aurora a kinase: discovery of selective cyclohexa[b]thiophenes with potent anticancer activity","author":"Abdel-Rahman","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130315","article-title":"Design, synthesis, and evaluation of 1,3,4-oxadiazole-based EGFR inhibitors","author":"Tang","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110445_bb0215","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1039\/D5RA01169H","article-title":"Design, synthesis, antiproliferative activity, and molecular dynamics simulation of pyrazoline-based derivatives as dual EGFR and HER-2 inhibitors","volume":"15","author":"Hafez","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110445_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118352","article-title":"Identification of pyrazole-acrylonitrile derivatives as potential anticancer agents and mechanistic insights","author":"Fabitha","year":"2025","journal-title":"Bioorg. Med. Chem."},{"issue":"43","key":"10.1016\/j.bioorg.2026.110445_bb0225","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1021\/acsomega.1c04063","article-title":"Synthesis, biological, and molecular docking studies on 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and their nanoparticles targeting colorectal cancer","volume":"6","author":"Kamal","year":"2021","journal-title":"ACS Omega"},{"issue":"26","key":"10.1016\/j.bioorg.2026.110445_bb0230","doi-asserted-by":"crossref","first-page":"18417","DOI":"10.1039\/D4RA03363A","article-title":"\u0392-Enaminonitrile in the synthesis of tetrahydrobenzo[b]thiophene candidates with DFT simulation, in vitro antiproliferative assessment, molecular docking, and modeling pharmacokinetics","volume":"14","author":"Elgubbi","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110445_bb0235","article-title":"New cycloalkyl[b]thiophenylnicotinamide-based \u03b1-glucosidase inhibitors as promising anti-diabetic agents: synthesis, in silico study, in vitro and in vivo evaluations","author":"Wang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110445_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142364","article-title":"Design, synthesis, and computational studies of novel pyrazoline-based dual EGFR\/HER-2 inhibitors with apoptotic antiproliferative activity","author":"Al-Wahaibi","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110445_bb0245","first-page":"o804","article-title":"Structure of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate at 163 K","volume":"60","author":"Larson","year":"2004","journal-title":"Acta Crystallogr. Sect. E Struct. Rep."},{"key":"10.1016\/j.bioorg.2026.110445_bb0250","article-title":"1,3,4-Oxadiazole-based EGFR inhibitors as anticancer therapeutics: SAR study and binding mode of interaction analysis","volume":"14","author":"Samanta","year":"2025","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"10.1016\/j.bioorg.2026.110445_bb0255","article-title":"Design, synthesis, and antiproliferative activity of antipyrine linked 2-aminoquinoline-3-carbonitrile derivatives as potential dual EGFR\/HER-2 inhibitors","volume":"95","author":"Mekheimer","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"46","key":"10.1016\/j.bioorg.2026.110445_bb0260","doi-asserted-by":"crossref","first-page":"42036","DOI":"10.1021\/acsomega.2c03908","article-title":"Synthesis and anticancer evaluation of novel indole based arylsulfonylhydrazides against human breast cancer cells","volume":"7","author":"Gaur","year":"2022","journal-title":"ACS Omega"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110445_bb0265","first-page":"8342","article-title":"Design, synthesis, and antiproliferative activity of new 5-chloro-indole-2-carboxylate and pyrrolo[3,4-b]indol-3-one derivatives as potent inhibitors of EGFR^T790M^\/BRAF^V600E^ pathways","volume":"27","author":"Al-Wahaibi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110445_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106198","article-title":"Repurposing N-hydroxy thienopyrimidine-2,4-diones (HtPD) as inhibitors of human cytomegalovirus pUL89 endonuclease: synthesis and biological characterization","volume":"129","author":"He","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109162","article-title":"Exploiting COX-2 engagement for amplifying anticancer potential of quinazoline-triazole conjugates with superior EGFR\/VEGFR-2 inhibition","volume":"166","author":"Serag","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110445_bb0280","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/cancers16061188","article-title":"Investigating the efficacy of EGFR-TKIs and anti-VEGFR combination in advanced non-small cell lung cancer: a meta-analysis","volume":"16","author":"Sakharkar","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110445_bb0285","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14650","article-title":"Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: an open-labeled randomized control trial","volume":"30","author":"Chen","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"32","key":"10.1016\/j.bioorg.2026.110445_bb0290","doi-asserted-by":"crossref","first-page":"36134","DOI":"10.1021\/acsomega.5c03795","article-title":"Targeting cancer with new morpholine-benzimidazole-oxadiazole derivatives: synthesis, biological evaluation, and computational insights","volume":"10","author":"Halimi Syla","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110445_bb0295","article-title":"Unveiling the therapeutic potential of 1,2,4-oxadiazole derivatives: an updated review","volume":"15","author":"Khasawneh","year":"2025","journal-title":"Results Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdc.2023.101073","article-title":"Design, synthesis and anticancer assessment of 1,2,3-triazole incorporated 1,3,4-oxadiazole-quinazoline derivatives","volume":"48","author":"Bhogireddy","year":"2023","journal-title":"Chem Data Collect."},{"issue":"52","key":"10.1016\/j.bioorg.2026.110445_bb0305","doi-asserted-by":"crossref","first-page":"38403","DOI":"10.1039\/D4RA06694D","article-title":"Design, synthesis, and antiproliferative activity of new 1,2,3-triazole\/quinazoline-4-one hybrids as dual EGFR\/BRAF^V600E^ inhibitors","volume":"14","author":"Mohamed","year":"2024","journal-title":"RSC Adv."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110445_bb0310","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110445_bb0315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110445_bb0320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110445_bb0325","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110445_bb0330","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Viegas-Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0335","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejmech.2014.10.059","article-title":"A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry","volume":"89","author":"Keri","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110445_bb0340","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/0118715230276678231102150158","article-title":"1, 3-Thiazole derivatives as a promising scaffold in medicinal chemistry: a recent overview","volume":"22","author":"Kushwaha","year":"2023","journal-title":"Anti-Inflammatory & Anti-Allergy Agents"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110445_bb0345","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1016\/j.ejmech.2010.05.047","article-title":"Design, synthesis and biological evaluation of 3, 5-diaryl-isoxazoline\/isoxazole-pyrrolobenzodiazepine conjugates as potential anticancer agents","volume":"45","author":"Kamal","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"26","key":"10.1016\/j.bioorg.2026.110445_bb0350","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.2174\/1568026616666160506130731","article-title":"Thiazole: a review on chemistry, synthesis and therapeutic importance of its derivatives","volume":"16","author":"Chhabria","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110445_bb0355","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110445_bb0360","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2017.05.014","article-title":"The 1, 2, 3-triazole ring as a bioisostere in medicinal chemistry","volume":"22","author":"Bonandi","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110445_bb0365","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1016\/j.bmc.2012.03.069","article-title":"Recent developments and biological activities of thiazolidinone derivatives: a review","volume":"20","author":"Jain","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"76","key":"10.1016\/j.bioorg.2026.110445_bb0370","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2014.02.027","article-title":"Bifunctional ethyl 2-amino-4-methylthiazole-5-carboxylate derivatives: synthesis and in vitro biological evaluation as antimicrobial and anticancer agents","author":"Rostom","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110445_bb0375","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1021\/jm070165j","article-title":"Design and synthesis of classical and nonclassical 6-arylthio-2, 4-diamino-5-ethylpyrrolo [2, 3-d] pyrimidines as antifolates","volume":"50","author":"Gangjee","year":"2007","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110445_bb0380","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ejmech.2010.01.022","article-title":"Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents","volume":"45","author":"Alqasoumi","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110445_bb0385","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ejmech.2009.10.044","article-title":"Synthesis, antitumor activity and molecular docking study of novel sulfonamide-Schiff\u2019s bases, thiazolidinones, benzothiazinones and their C-nucleoside derivatives","volume":"45","author":"Kamel","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110445_bb0390","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.bmcl.2009.05.044","article-title":"Synthesis of 4-substituted pyrido [2, 3-d] pyrimidin-4 (1H)-one as analgesic and anti-inflammatory agents","volume":"19","author":"El-Gazzar","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110445_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26735","article-title":"Synthesis, anticancer activity and molecular docking of new quinolines, quinazolines and 1, 2, 4-triazoles with pyrido [2, 3-d] pyrimidines","volume":"10","author":"Abu-Hashem","year":"2024","journal-title":"Heliyon"},{"issue":"6\u20137","key":"10.1016\/j.bioorg.2026.110445_bb0400","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/minf.201000061","article-title":"Best practices for QSAR model development, validation, and exploitation","volume":"29","author":"Tropsha","year":"2010","journal-title":"Mol. Inf."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110445_bb0405","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/13880209.2025.2547744","article-title":"Design, evaluation, cytotoxic activity, molecular docking, ADMET analysis, and dynamic simulations and the preparation of new isoxazoles, thiazoles, 1, 3-thiazines, and thiazolopyrimidines derived from quinoline-pyridopyrimidines","volume":"63","author":"Abu-Hashem","year":"2025","journal-title":"Pharm. Biol."},{"issue":"48","key":"10.1016\/j.bioorg.2026.110445_bb0410","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110445_bb0415","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.110445_bb0420","unstructured":"Schr\u00f6dinger Release 2024\u20131: Maestro. Schr\u00f6dinger LLC, New York, NY, USA."},{"key":"10.1016\/j.bioorg.2026.110445_bb0425","unstructured":"Schr\u00f6dinger Release 2026-2: LigPrep, Schr\u00f6dinger, LLC, New York, NY, 2025."},{"key":"10.1016\/j.bioorg.2026.110445_bb0430","unstructured":"Schr\u00f6dinger LL, New York, NY, USA, 2012, LigPrep. version. 2016;3."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110445_bb0435","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","article-title":"Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution","volume":"24","author":"Greenwood","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"45","key":"10.1016\/j.bioorg.2026.110445_bb0440","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"issue":"D1","key":"10.1016\/j.bioorg.2026.110445_bb0445","doi-asserted-by":"crossref","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: new data content and improved web interfaces","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110445_bb0450","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1747-0285.2006.00384.x","article-title":"PHASE: a novel approach to pharmacophore modeling and 3D database searching","volume":"67","author":"Dixon","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110445_bb0455","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","article-title":"PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results","volume":"20","author":"Dixon","year":"2006","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110445_bb0460","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1021\/ja00226a005","article-title":"Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins","volume":"110","author":"Cramer","year":"1988","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110445_bb0465","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1093-3263(01)00123-1","article-title":"Beware of q2!","volume":"20","author":"Golbraikh","year":"2002","journal-title":"J. Mol. Graph. Model."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110445_bb0470","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/qsar.200610151","article-title":"Principles of QSAR models validation: internal and external","volume":"26","author":"Gramatica","year":"2007","journal-title":"QSAR Comb. Sci."},{"key":"10.1016\/j.bioorg.2026.110445_bb0475","series-title":"GeinDock Suite","author":"Geinforce Technology Private Limited","year":"2026"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110445_bb0480","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110445_bb0485","article-title":"Molecular docking, validation, dynamic simulation and pharmacokinetic prediction of natural compounds against Mycobacterium tuberculosis Beta-lactamase BlaC","author":"Sreekumar","year":"2025","journal-title":"BioRxiv"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:28:24Z","timestamp":1791260904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":97,"alternative-id":["S0045206826009818"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110445","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atom-based 3D-QSAR, pharmacophore modelling and molecular dynamics guided identification of thienopyrimidinone derivatives targeting EGFR in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110445"}}